Literature DB >> 29201885

Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer.

Takehiro Uemura1, Toyoaki Hida1.   

Abstract

Entities:  

Year:  2017        PMID： 29201885      PMCID： PMC5690958          DOI： 10.21037/atm.2017.08.36

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

3.  Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.

Authors:  Tatsuya Yoshida; Yuko Oya; Kosuke Tanaka; Junichi Shimizu; Yoshitsugu Horio; Hiroaki Kuroda; Yukinori Sakao; Toyoaki Hida; Yasushi Yatabe
Journal:  Lung Cancer       Date:  2016-04-23       Impact factor: 5.705

4.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

Review 5.  Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors:  Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal:  Cancer Discov       Date:  2017-01-25       Impact factor: 39.397

6.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

7.  Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).

Authors:  Eiji Iwama; Yasushi Goto; Haruyasu Murakami; Taishi Harada; Shinsuke Tsumura; Hiroyuki Sakashita; Yoshiaki Mori; Noriaki Nakagaki; Yuka Fujita; Masahiro Seike; Akihiro Bessho; Manabu Ono; Akihito Okazaki; Hiroaki Akamatsu; Ryotaro Morinaga; Shinichiro Ushijima; Takayuki Shimose; Shoji Tokunaga; Akinobu Hamada; Nobuyuki Yamamoto; Yoichi Nakanishi; Kenji Sugio; Isamu Okamoto
Journal:  J Thorac Oncol       Date:  2017-02-24       Impact factor: 15.609

8.  Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Authors:  Johannes M Heuckmann; Hyatt Balke-Want; Florian Malchers; Martin Peifer; Martin L Sos; Mirjam Koker; Lydia Meder; Christine M Lovly; Lukas C Heukamp; William Pao; Ralf Küppers; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

9.  Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.

Authors:  Yuan-Yuan Lei; Jin-Ji Yang; Xu-Chao Zhang; Wen-Zhao Zhong; Qing Zhou; Hai-Yan Tu; Hong-Xia Tian; Wei-Bang Guo; Lu-Lu Yang; Hong-Hong Yan; Hua-Jun Chen; Zhi Xie; Jian Su; Jie-Fei Han; Yi-Long Wu
Journal:  Clin Lung Cancer       Date:  2015-09-21       Impact factor: 4.785

10.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316
View more
  2 in total

Review 1.  Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy.

Authors:  Tiziana Vavalà; Silvia Novello
Journal:  Ther Adv Med Oncol       Date:  2018-08-03       Impact factor: 8.168

2.  Mutated p53 Promotes the Symmetric Self-Renewal of Cisplatin-Resistant Lung Cancer Stem-Like Cells and Inhibits the Recruitment of Macrophages.

Authors:  Yu Xu; Zhi Xu; Qi Li; Liang Guo; Yao Wang; Jianchun Zhou; Guansong Wang; Yuliang Liu
Journal:  J Immunol Res       Date:  2019-10-31       Impact factor: 4.818
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.